Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Lymphoma
Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?
Related Questions
What is the best treatment approach to a patient with HGBCL w/ FISH translocation of BCL-6 and c-Myc given new classification of this entity?
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
For patients with primary CNS lymphoma and less than a CR to chemotherapy, in what situation would you consider partial or focal radiation?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you manage a healthy 31 younger patient with nodular lymphocyte predominant Hodgkin lymphoma with severe hemolytic anemia but no other symptoms that responded to steroids?
